International Journal of Rheumatology / 2009 / Article / Tab 1

Research Article

Differentiation of PSRA due to Group A and due to Nongroup A Streptococci in Patients with Early Arthritis and Elevated Antisteptolysin-O at Presentation

Table 1

Overview of 45 patients with acute arthritis subdivided into post-streptococcal reactive arthritis (PSRA) probably due to group A streptococci (GAS) in 20, probably due to nongroup A streptococci (NGAS) in 16, and 9 non-PSRA patients. Clinical data are taken at presentation; maximum serological data are tabulated. Legend: IgM-RF = rheumatoid factor (IgM type), ANA = antinuclear antibodies.

PSRA Presumed GASPresumed NGAS Non-PSRA

Number of females/males 11/9 7/9 6/3
Mean age (SD) in year [range] 33 (11) [17–54] 37 (17) [12–55] 40 (16) [14–70]
Positivity for
HLA-B271 (5%) 0 (0%) 0 (0%)
IgM-RF 1 (5%) 0 (0%)5 (55%)
ANA 5 (25%) 0 (0%) 2 (22%)

Antistreptolysin-O (ASO)
200 20 (100%) 16 (100%) 6 (67%)
mean value (SEM)1390 (235) 1055 (130) 1088 (360)
Antideoxyribonuclease-B (ADB)
200 20 (100%)2 (12.5%) 6 (67%)
mean value (SEM) 2730 (450)295 (67) 340 (90)
ASO/ADB ratio
1.4 20 (100%)0 (0%) 3 (33%)
mean value (SEM) 0.62 (0.06) 6.2 (1.2) 9.4 (5.0)

Positive throat culture 7x GAS 2x NGAS 1x NGAS
Arthritic joints; mean number (SEM) 5.2 (1.3)*1.9 (0.4)3.4 (1.2)
monoarthritis 8 (40%) 10 (63%) 3 (33%)
oligoarthritis7 (35%) 5 (32%) 3 (33%)
polyarthritis 5 (25%)1 (6%) 3 (33%)
Mean duration in weeks (SD)25 (10)* 5 (2.5)
exceeding 2 months10 (50%) 5 (31%)
exceeding 6 months 5 (25%) 0 (0%)
Pericarditis 1 (5%)0 (0%) 0 (0%)
Pneumonitis 1 (5%) 0 (0%) 0 (0%)
Erythema nodosum/multiforme 1 (5%) 0 (0%) 1 (11%)
Cholestatic hepatitis2 (10%) 0 (0%)0 (0%)
Tenosynovitis 4 (20%)0 (0%)3 (33%)

-value <.05 for comparison presumed GAS-induced and presumed NGAS-induced PSRA patients. GAS no. is presumed as the causative organism if the ASO/antiDNaseB ratio is <1.4; NGAS is presumed if ASO/antiDNaseB ratio >1.5.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.